A domesticated photoautotrophic microbial community as a biofilm model system for analyzing the influence of plastic surfaces on invertebrate grazers in limnic environments

The environmental fate of plastic particles in water bodies is influenced by microbial biofilm formation. Invertebrate grazers may be affected when foraging biofilms on plastics compared to biofilms on natural substrata but the mechanistic basis for these effects is unknown. For analyzing these effects in ecotoxicological assays stable and reproducible biofilm communities are required that are related to the environmental site of interest. Here, a defined biofilm community was established and used to perform grazing experiments with a freshwater snail. For this, snippets of different plastic materials were incubated in the photic zone of three different freshwater sites. Amplicon sequencing of biofilms formed on these snippets showed that the site of incubation and not the plastic material dominated the microbial community composition. From these biofilms, individual microbial strains as well as photoautotrophic consortia were isolated; these consortia consisted of heterotrophic bacteria that were apparently nourished by microalga. While biofilms formed by defined dual cultures of a microalga and an Alphaproteobacterium were not accepted by the snail P. fontinalis, a photoautotrophic consortium (Co_3) sustained growth and metabolism of this grazer. Amplicon sequencing revealed that consortium Co_3, which could be stably maintained on solid medium under photoautotrophic conditions, reproducibly formed biofilms of a defined composition on three different plastic materials and on glass surfaces. In conclusion, our study shows that the generation of domesticated photoautotrophic microbial communities is a valid novel approach for establishing laboratory ecotoxicological assays with higher environmental relevance than those based on defined microbiota

Market penetration of vehicle safety systems 2021

Aufgabe der Studie war es, die Ausstattung der Pkw in Deutschland mit Fahrzeugsicherheitssystemen umfassend zu erheben. Ab 2013 hat infas die Studie in Zusammenarbeit mit dem Institut für Kraftfahrzeuge (ika) regelmäßig im zweijährigen Abstand durchgeführt, um Veränderungen bei der Marktdurchdringung der Systeme festzustellen. 2021 wurden dazu 5.006 Haushalte zur Ausstattung eines ihnen zur Verfügung stehenden Fahrzeugs befragt. Für die Befragung wurden insgesamt 61 Fahrzeugsicherheitssysteme ausgewählt. Die weiteste Verbreitung haben weiterhin passive Sicherheitssysteme wie Airbags. Sowohl Front­ als auch Seitenairbags gehören zur Standardausstattung in allen Fahrzeugsegmenten. Gleiches gilt mittlerweile auch für Seat Belt Reminder und Gurtstraffer. Neuere passive Systeme, insbesondere zum Fußgängerschutz, sind dagegen überwiegend in neueren Modellen der oberen Mittel­ und Oberklasse vorhanden. Zur Fahrzeugausstattung gehören gleichzeitig aktive Systeme, die Risiken vermeiden oder auch einzelne Fahraufgaben übernehmen. Die häufigsten Vertreter aus dieser Gruppe sind Bremsassistent, ESP und Tempomat. Bereits 90 Prozent der Fahrzeuge sind mit ESP ausgestattet, das seit 2011 gesetzlich vorgeschrieben ist. Auch die Tagfahrleuchte ist aufgrund einer EU­Richtlinie bereits in 61 Prozent aller Fahrzeuge verbaut und wird in Zukunft eine volle Marktdurchdringung erreichen. Zu den neueren Entwicklungen gehören teilautomatisierte Systeme, wie der Überhol­ und Autobahnassistent, die bereits dem Automatisierungslevel 2 der Norm SAE J3016 entsprechen. Diese sind aufgrund der teuren und aufwendigen Technik jedoch bislang nur bei einem kleinen Teil der Geländewagen/SUV sowie der oberen Mittel­ und Oberklasse zu finden. In den letzten Jahren nimmt besonders die Ausstattung im Segment SUV stark zu, sodass Fahrzeuge dieses Segments inzwischen bei einigen Systemen besser ausgestattet sind als Fahrzeuge der oberen Mittel­ und Oberklasse. Dies hängt auch mit der stetig wachsenden Anzahl der Neuzulassungen in diesem Bereich zusammen. Die Anzahl der Sicherheitssysteme nimmt mit der jährlichen Fahrleistung und der Nutzungshäufigkeit ebenso zu wie bei jüngeren Fahrzeugen und Dienstwagen. Betrachtet man die Ausstattungsraten nach Fahrzeugsegmenten zeigt sich ein Muster: Sind Systeme insgesamt selten, unterscheiden sich die Anteile innerhalb der verschiedenen Fahrzeugsegmente teilweise erheblich.The aim of this study was to investigate the safety systems equipment of passenger cars in Germany. Since 2013 the study has been conducted by infas in cooperation with the Institute of Automotive Engineering (ika) in a two year interval in order to detect changes in the market penetration of the systems. In 2021, 5,006 households were interviewed on the equipment of their vehicles. 61 vehicle safety systems were selected for the survey. The most common systems are passive safety systems such as airbags. Both front and side airbags are now standard equipment in all vehicle segments. In contrast, newer passive systems especially for pedestrian protection are predominantly present in newer models of the upper middle and upper class. Vehicle equipment also includes active systems that avoid risks or take on individual driving tasks. Most common among them are Brake Assist, ESP and Cruise Control. More than 90 percent of the vehicles are already equipped with ESP, which is required by law since 2011. Due to an EU directive, the Daytime Running Light is already installed in 61 percent of all vehicles and will achieve full market penetration in the future. The latest developments include systems with partial automatization, such as Overtaking Assistant and Motorway Assistant that already fulfil automation level 2 of the SAE J3016 standard. Due to the expensive and complex technology they can only be found in a small part in the segment of SUVs and all­terrain vehicles as well as in the upper middle and upper class segments. In recent years equipment in the segment of SUVs in particular has increased significantly with the result that vehicles in this segment are now better equipped with some systems than vehicles in the upper middle and upper class. This is also related to the high number of new registrations in this segment. The number of systems increases with annual distance travelled and frequency of use, as well as for newer vehicles and company cars. Looking at the equipment rates for vehicle segments a pattern emerges: if systems are rare overall, the proportions within the various vehicle segments differ, sometimes considerably

Human exome and mouse embryonic expression data implicate ZFHX3, TRPS1, and CHD7 in human esophageal atresia

Introduction: Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) occurs approximately 1 in 3.500 live births representing the most common malformation of the upper digestive tract. Only half a century ago, EA/TEF was fatal among affected newborns suggesting that the steady birth prevalence might in parts be due to mutational de novo events in genes involved in foregut development. Methods: To identify mutational de novo events in EA/TEF patients, we surveyed the exome of 30 case-parent trios. Identified and confirmed de novo variants were prioritized using in silico prediction tools. To investigate the embryonic role of genes harboring prioritized de novo variants we performed targeted analysis of mouse transcriptome data of esophageal tissue obtained at the embryonic day (E) E8.5, E12.5, and postnatal. Results: In total we prioritized 14 novel de novo variants in 14 different genes (APOL2, EEF1D, CHD7, FANCB, GGT6, KIAA0556, NFX1, NPR2, PIGC, SLC5A2, TANC2, TRPS1, UBA3, and ZFHX3) and eight rare de novo variants in eight additional genes (CELSR1, CLP1, GPR133, HPS3, MTA3, PLEC, STAB1, and PPIP5K2). Through personal communication during the project, we identified an additional EA/TEF case-parent trio with a rare de novo variant in ZFHX3. In silico prediction analysis of the identified variants and comparative analysis of mouse transcriptome data of esophageal tissue obtained at E8.5, E12.5, and postnatal prioritized CHD7, TRPS1, and ZFHX3 as EA/TEF candidate genes. Re-sequencing of ZFHX3 in additional 192 EA/TEF patients did not identify further putative EA/TEF-associated variants. Conclusion: Our study suggests that rare mutational de novo events in genes involved in foregut development contribute to the development of EA/TEF

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA